Gilead Has Biggest Gain Since 2012 After Hint of Virus Results
This article is for subscribers only.
Gilead Sciences Inc. shares had their biggest intraday gain since 2012 on Friday after a report that a group of patients being treated in Chicago were “seeing rapid recoveries in fever and respiratory symptoms.”
The report, from the medical news publication Stat, cited a video made by a researcher at the University of Chicago who is helping conduct a trial of Gilead’s drug remdesivir. The researcher, infectious disease professor Kathleen Mullane, said that most patients had been discharged from the hospital and only two had died, according to Stat.